Top News

J&J Completes $2 Billion Ambrx Acquisition, Boosts Pipeline for Next-Gen ADCs

March 07, 2024

Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.

Daiichi Sankyo Invests Roughly $1.08 Billion to Expand German Production and Development Site for ADCs

February 22, 2024

Daiichi Sankyo is investing approximately €1 billiion (US$1.08 billion) to expand its Pfaffenhofen an der Ilm, Germany, site for ADC development and production.

Novartis to Acquire MorphoSys for Roughly $2.9 Billion

February 08, 2024

Through a €2.7 billion (US$2.9 billion) acquisition of MorphoSys, Novartis will get pelabresib, a late-stage drug candidate in development for cancer treatment.

Novo Holdings to Acquire Catalent in Deal Valued at $16.5 billion

February 05, 2024

Novo Holdings has entered into a merger agreement with Catalent and will acquire Catalent in a deal valued at $16.5 billion.

Sanofi to Aquire Inhibrx for $1.7 Billion

January 29, 2024

The acquisition adds a potential rare disease asset to Sanofi’s alpha-1 antitrypsin deficiency pipeline.

Merck to Acquire Harpoon Therapeutics in Deal Valued at $680 Million

January 16, 2024

Through the acquisition of Harpoon Therapeutics, Merck will gain an investigational delta-like ligand 3-targeting T-cell engager under development for cancer treatment.

GSK to Acquire Aiolos Bio, Expands Respiratory Portfolio

January 09, 2024

In a deal worth up to $1.4 billion, GSK aims to acquire Aiolos Bio and gain an expanded pipeline of biologic-based respiratory therapeutic candidates.

AstraZeneca Poised to Acquire Cell Therapy Developer, Gracell, in Deal Valued at $1.2 Billion

January 04, 2024

AstraZeneca’s acquisition of Gracell includes a clinical-stage autologous cell therapy targeting hematologic malignancies and autoimmune diseases and a proprietary manufacturing platform.

AstraZeneca to Acquire Icosavax in Deal Valued at Approximately $1.1 Billion

January 02, 2024

With the acquisition, AstraZeneca will gain a potential RSV and hMPV combination vaccine.

Bristol Myers Squibb and SystImmune Enter Global ADC Collaboration Worth Potentially up to $8.4 Billion

December 19, 2023

Bristol Myers Squibb and SystImmune plan to co-develop and co-commercialize lead ADC candidate for cancer treatment in US.